GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77
详细信息 查看全文
- 作者：M. Desai ; C. A. Cull ; V. A. Horton ; M. R. Christie ; E. Bonifacio ; V. Lampasona ; P. J. Bingley ; J. C. Levy ; I. R. Mackay and P. Zimmet ; et al.
- 关键词：Antibody persistence ; Clinical progression ; GAD antibodies ; Latent autoimmune diabetes in adults ; Type 1 diabetes
- 刊名：Diabetologia
- 出版年：2007
- 出版时间：October, 2007
- 年：2007
- 卷：50
- 期：10
- 页码：2052-2060
- 全文大小：207 KB
- 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Internal Medicine
Metabolic Diseases
Human Physiology - 出版者：Springer Berlin / Heidelberg
- ISSN：1432-0428
文摘
Aims/hypothesis Latent autoimmune diabetes in adults (LADA) is a slowly progressive form of autoimmune diabetes, with autoantibodies to islet proteins developing in older patients who have no immediate requirement for insulin therapy. Markers of its clinical course are uncharacterised. The aim of this study was to determine whether persistence of, or changes in, GAD65 autoantibodies (GADAs) in the LADA patients who participated in the United Kingdom Prospective Diabetes Study (UKPDS) were associated with disease progression or insulin requirement.